Warum steigt der Aktienkurs von ELI LILLY AND CO?
Bullen sagen
Access and product mix
Medicare Bridge expansion combined with a differentiated mix of oral, injectable, and combination obesity medicines is poised to increase patient access and support retention through broader treatment choices.
Clinical efficacy of next-generation therapies
Phase 2 results showing eloralintide combined with tirzepatide delivered superior weight loss and improved blood sugar control establish a higher-efficacy benchmark that could drive adoption if confirmatory trials validate the findings.
Pipeline diversification and investor visibility
An investor event showcasing the next-generation obesity pipeline alongside an oral SERD candidate and an Alzheimer’s program, together with regulatory progress and oncology growth, supports the case for durable top-line expansion beyond core diabetes products.
Tolerability and discontinuation risk
Higher discontinuation rates at the highest combination and EloraTZP doses raise tolerability concerns that may require dose optimization and could complicate late-stage development or commercial uptake.
Launch execution and dosing dynamics
A reset in Foundayo launch expectations, coupled with most prescriptions starting at low doses, creates revenue ramp uncertainty if patients persist on lower-dose regimens for cost reasons.
Operational and coverage uncertainty
Operational frictions, patient confusion about the Medicare Bridge program, and uncertainty about future program coverage could limit the anticipated access gains and reduce clinic-level uptake.
